Title

Methotrexate in Psoriasis and Psoriatic Arthritis.

Authors

Laura C Coates
Joseph F Merola
Suzanne M Grieb
Philip Mease, Providence St. Joseph HealthFollow
Kristina Callis Duffin

Document Type

Article

Publication Date

6-1-2020

Publication Title

The Journal of rheumatology. Supplement

Abstract

Methotrexate (MTX) is the most commonly prescribed first-line therapy in psoriatic arthritis (PsA) internationally and is also commonly used in the treatment of psoriasis. However, data supporting its use in PsA are limited and significant toxicities can occur. This article summarizes a debate at the 2019 Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) annual meeting that focused on the use of MTX in psoriasis and PsA. Four clinicians and 1 patient research partner presented clinical study data and the patient experience summarizing the efficacy, tolerability, and toxicity of MTX for both skin and musculoskeletal manifestations. A survey of attending GRAPPA members collected data on current and planned future use of MTX across the world.

Clinical Institute

Orthopedics & Sports Medicine

Department

Rheumatology

Department

Orthopedics

Recommended Citation

Coates, Laura C; Merola, Joseph F; Grieb, Suzanne M; Mease, Philip; and Callis Duffin, Kristina, "Methotrexate in Psoriasis and Psoriatic Arthritis." (2020). Articles, Abstracts, and Reports. 3259.
https://digitalcommons.providence.org/publications/3259